Cancer Family
Cutaneous Melanocytic Neoplasm
CI-CAN-00000154Explore in graph →
Non-malignant81 active trials1 approved drugs61 evidence items
- NCIt
- C7161
Loading cancer entity…
Cancer Family
CI-CAN-00000154Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2016 | clinicaltrials |
| NCT00026221 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01729663 | Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | unknown | Phase 2 / Phase 3 | 108 | Laboratorio Pablo Cassara S.R.L.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00866177 | MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 167 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2015 | clinicaltrials |
| NCT00470470 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02142335 | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma | unknown | Phase 2 | 17 | California Cancer Assocaties for Research & ExcellenceOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00925314 | A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma | unknown | Phase 2 | 20 | Cosmo BioscienceINDUSTRY | 1 | Feb 13, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Oct 24, 2016source: clinicaltrials